JPMorgan raised the firm’s price target on Teva to $11 from $9 and keeps an Underweight rating on the shares ahead of the earnings report. On 2024, the analyst sees TEVA generating modest revenue growth with Austedo, generic Revlimid and Uzedy, offsetting headwinds for Bendeka/Treanda and Copaxone. Investor sentiment has become more positive on shares, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA:
